

34. A method for protecting a mucous membrane during radiotherapy or combined radiochemotherapy comprising applying to the mucous membrane prior to the radiotherapy or combined radiochemotherapy an effective amount of a compound chosen from flavonoids and isoflavonoids in the form of a mixture with a vehicle which is liquid at room temperature and which gels at the temperature of the mucous membrane and which is capable of adhering to the mucous membrane because of its gelled state.

35. A pharmaceutical composition for the treatment of radiomucositis or of chemomucositis induced by radiotherapy or combined radiochemotherapy, comprising an effective quantity of a compound chosen from flavonoids and isoflavonoids in the form of a mixture with a vehicle which is liquid at room temperature and which gels at the temperature of the mucous membrane and which is capable of adhering to the mucous membrane because of its gelled state.

36. The composition according to claim 35, whose vehicle is an aqueous vehicle and comprise a mixture of 0.05 to 5% by weight of an agent conferring viscosity and of 1 to 20% by weight of an agent modifying the viscosity according to the temperature.

37. The composition according to claim 36, in which the agent modifying the viscosity according to the temperature is chosen from poloxamers, poloxamines, and divinylbenzenesorbitol compounds.
38. The composition according to claim 35, whose vehicle is an aqueous vehicle and comprises a mixture of 0.1 to 3% by weight of an agent conferring viscosity and of 5 to 20% by weight of an agent modifying the viscosity according to the temperature.
39. The composition according to claim 38, in which the agent modifying the viscosity according to the temperature is chosen from poloxamers, poloxamines, and divinylbenzenesorbitol compounds.
40. The composition according to claim 35, in which the flavonoid is chosen from the rutosides, diosmin, quercitin, tangeretin and hesperidin.
41. The composition according to claim 35, in which the isoflavonoid is genistein, daidzin or glycitin.
42. The composition according to claim 40, in which the rutoside is rutin.